Article
Surgery
Quyen D. Chu, Mei-Chin Hsieh, Yong Yi, John M. Lyons, Xiao-Cheng Wu
Summary: A study was conducted to evaluate the outcomes of breast-conserving therapy (BCT) and mastectomy (MST) for women with early-stage breast cancer (ESBC). The results showed that BCT yielded better survival rates than MST for all subtypes of ESBC. The role of mastectomy in the treatment of ESBC should be reassessed in future clinical trials.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2022)
Article
Multidisciplinary Sciences
Tao Huang, Qigen Fang, Lianjie Niu, Lina Wang, Xianfu Sun
Summary: Breast conservation surgery (BCS) has shown superiority over mastectomy in treating early-stage adenoid cystic carcinoma of the breast (BACC). Comparing overall survival (OS) and disease-specific survival (DSS) between BCS and mastectomy groups, it was found that BCS achieved higher 10-year OS and DSS rates for stage I/II BACC.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Jiali Ji, Shushu Yuan, Jiawei He, Hong Liu, Lei Yang, Xuexin He
Summary: This study compared the efficacy of breast-conserving therapy (BCT) and mastectomy in early-stage breast cancer patients using the SEER database. The results showed that BCT was associated with improved overall survival (OS) and breast cancer-specific survival (BCSS) compared to mastectomy. Patients with different subtypes and age groups also showed better survival outcomes with BCT compared to mastectomy.
Article
Surgery
Yazan A. Masannat, Nicola Rocco, Emanuele Garreffa, Bahadir M. Gulluoglu, Ashutosh Kothari, Anna Maglia, Maurizio B. Nava, Omar S. Omar, Shelley Potter, Giuseppe Catanuto
Summary: The survey aimed to examine the differences in the definition and management of multifocal and multicentric breast cancer globally. The results from 743 physicians across 100 countries provide a clear understanding of international practices, particularly in relation to the controversial use of MRI.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Oncology
Dang Van Nguyen, Sang-Won Kim, Young-Taek Oh, O. Kyu Noh, Yongsik Jung, Mison Chun, Dae Sung Yoon
Summary: Young women undergoing breast conserving therapy have a higher risk of local recurrence compared to mastectomy alone. Despite aggressive salvage treatments, those with local recurrence after breast conserving therapy have poor prognosis. Novel systemic treatments are needed to improve outcomes for young women with breast cancer undergoing breast conserving therapy.
Article
Oncology
Javier I. J. Orozco, Jennifer K. Keller, Shu-Ching Chang, Crystal E. Fancher, Janie G. Grumley
Summary: A study comparing the overall survival of young women with breast cancer undergoing upfront breast-conserving therapy and mastectomy found that the overall survival was similar regardless of the surgical approach.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Zhi-Hong Sun, Chuang Chen, Xin-Wen Kuang, Jun-Long Song, Sheng-Rong Sun, Wei-Xing Wang
Summary: This study found that, compared to mastectomy, breast-conserving therapy (BCT) can provide better breast cancer-specific survival and overall survival benefits in young white patients under 40 with early-stage breast cancer, especially in the 36 to 40 years age group.
Letter
Medicine, General & Internal
Marie Fefferman, Kyra Nicholson, Kristine Kuchta, Catherine Pesce, Katherine Kopkash, Katharine Yao
Summary: This study builds on previous research to assess the ongoing increase in rates of bilateral mastectomy using the National Cancer Database.
Article
Medicine, General & Internal
Gang Liu, Xiangyi Kong, Qichen Dai, Han Cheng, Jing Wang, Jidong Gao, Yipeng Wang
Summary: This article reports on the clinical characteristics and prognosis of Chinese breast cancer patients, evaluating their overall survival and disease-free survival. The study highlights the importance of personalized treatment strategies and emphasizes the advantages of breast-conserving surgery.
Article
Oncology
Song Wang, Yiyuan Zhang, Fangxu Yin, Xiaohong Wang, Zhenlin Yang
Summary: In women with early-stage IMPC, breast-conserving treatment was found to be at least equivalent to mastectomy in terms of survival outcomes. BCT should be recommended as the standard surgical treatment, especially for patients with T2 disease, when both procedures are feasible.
FRONTIERS IN ONCOLOGY
(2021)
Article
Surgery
Quyen D. Chu, Mei-Chin Hsieh, John M. Lyons, Xiao-Cheng Wu
Summary: Louisiana has a high breast cancer mortality rate despite a lower incidence rate. Research has shown that compared to breast-conserving surgery plus radiation, mastectomy leads to poorer overall survival and breast cancer-specific survival rates.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2021)
Article
Oncology
Yushuang He, Xinyi Gao, Jierong Wu, Xuelu Li, Zhenhai Ma
Summary: This population-based cohort study suggests that breast conservation therapy is at least equivalent to mastectomy in male breast cancer patients.
CLINICAL BREAST CANCER
(2022)
Article
Environmental Sciences
Mohammad Shoaib Abrahimi, Mark Elwood, Ross Lawrenson, Ian Campbell, Sandar Tin Tin
Summary: This study investigated the type of loco-regional treatment and associated factors in New Zealand women with early-stage breast cancer eligible for breast conserving surgery. Results showed variations in the receipt of BCS+RT across demographic and clinical factors, with higher breast cancer-specific mortality risk for women receiving MTX alone compared to BCS+RT. Further research is needed to explore the potential advantages of BCS+RT over alternative treatments.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Surgery
Zhi Li, Ruipeng Zhao
Summary: The aim of this study was to investigate the impacts of breast conservation therapy (BCT) and mastectomy on heart-specific mortality in breast cancer patients. Through follow-up and multivariate regression analysis of breast cancer patients, it was found that BCT significantly decreased heart-specific mortality compared with mastectomy.
Article
Oncology
Mirat Shah, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, William F. Pierce, Abhilasha Nair, Jonathan Herz, Kim J. Robertson, Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The FDA has approved pembrolizumab in combination with chemotherapy for treating high-risk, early-stage triple-negative breast cancer. The addition of pembrolizumab significantly improves pathological complete response rate and event-free survival. Pembrolizumab demonstrates benefits regardless of tumor PD-L1 status.
CLINICAL CANCER RESEARCH
(2022)